Cellphire Therapeutics announced successful completion of its CRYPTICS Phase 2/3 clinical trial, demonstrating that its investigational frozen platelet therapy CLPH-511 met the primary efficacy endpoint in treating acute hemorrhage. The randomized controlled trial compared dimethyl sulfoxide cryopreserved platelets to liquid stored platelets in patients undergoing cardiopulmonary bypass surgery.
Primary Endpoint Achievement
The CRYPTICS study achieved its primary efficacy endpoint of 24-hour chest tube drainage, with a difference in least squares means of 142.0 mL and a 95.576% confidence interval of volume difference lower than the noninferiority margin. Sensitivity analyses of the primary endpoint were consistent and supportive of the main findings.
A comprehensive review of study efficacy data based on clinically relevant secondary endpoints further supported the noninferiority of CLPH-511 to room temperature platelets. Adverse events were well balanced between the two treatment groups, indicating a favorable safety profile.
Addressing Critical Medical Need
CLPH-511 (Frozen (Activated) Platelets) Injectable Suspension is being developed as an alternative to room-temperature platelets to address a US public health crisis caused by platelet shortages. Hemorrhage represents a leading cause of preventable death in the United States, responsible for nearly 40% of early trauma-related mortality in civilians less than 65 years of age and approximately 90% of potentially survivable deaths in combat.
The clinical burden is substantial, with hemorrhage accounting for more than 60,000 deaths nationwide each year and remaining the number one cause of preventable deaths in the US for individuals under 45 years of age. Platelet shortages further exacerbate this crisis, leaving patients without timely, life-saving interventions.
Clinical Development Progress
The CRYPTICS study (NCT04709705) was designed as a Phase 2/3 adaptive trial investigating the use of CLPH-511 in acute hemorrhage. The completion of this trial represents a significant milestone for Cellphire's clinical program and advancement of its platelet therapeutics portfolio.
"This is an important step in advancing our platelet-based platform," said Damien Bates, Chief Medical Officer of Cellphire Therapeutics. "We look forward to discussing these important results with the FDA."
Regulatory Pathway and Next Steps
Cellphire is now preparing for its End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA). The company will continue to advance the clinical development of CLPH-511, leveraging the benefits of the product's Fast Track and Medical Priority Product designations to bring this innovative therapy to patients as quickly and efficiently as possible.
Topline data from the study will be presented at the upcoming 2025 AABB Annual Meeting in San Diego by Dr. Glenn Whitman of Johns Hopkins Medical Institute during the Educational Session, "Update on the Use of Cryopreserved Platelets in Acute Surgical Settings," scheduled for Sunday, October 26, 2025.
Technology Platform
Cellphire Therapeutics is developing next-generation, allogeneic, platelet-derived therapies with a portfolio that includes CLPH-511, a cryopreserved platelet therapy with extended shelf life, and CLPH-211, part of the FPH® family of freeze-dried, platelet-derived hemostatic agents. The company's differentiated technologies are designed to address significant unmet health system and medical needs across various clinical settings including acute bleeding associated with surgery, trauma and traumatic brain injury.
